Prophylactic treatment of migraine with an angiotensin II receptor blocker: A randomized controlled trial

JAMA

Volumn 289, Issue 1, 2003, Pages 65-69

  Tronvik, Erling ^a,b   Stovner, Lars J ^b   Helde, Grethe ^b   Sand, Trond ^b   Bovim, Gunnar ^b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DEPRESSION; DISABILITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 0037218941     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.1.65     Document Type: Article

References (25)

1. Phillips P. Migraine as a woman's issue - Will research and new treatments help? JAMA. 1998;280 (23):1975-1976.
2. Challenges for the 21st Century: A Gender Perspective on Nutrition Through the Life Cycle. ACC/SCN symposium report, nutrition policy paper 17; November 1998:82. Available at: http://acc.unsystem.org/scn/Publications/NPP/npp17.pdf. Accessed May 12, 2002.
3. Ferrari MD, Roon KI, Lipton RB, et al. Oral Triptans (serotonin 5-HT agonists) in acute migraine treatment. Lancet. 2001;358:1668-1675.
4. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril). BMJ. 2001; 322:19-22.
5. Lalloo UG, Barnes PJ, Chung KF. Pathophysiology and clinical presentations of cough. J Allergy Clin Immunol. 1996;98:S91-S96.
6. Pillans PI, Coulter DM, Black P. Angiooedema and urticaria with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol. 1996;51:123-126.
7. Stoukides CA, McVoy HJ, Kaul AF. Candesartan cilexetil: An angiotensin II receptor blocker. Ann Pharmacother. 1999;33:1287-1298.
8. Etminan M, Mitchell A, Levine MA, et al. Efficacy of angiotensin II receptor antagonists in preventing headache. Am J Med. 2002;112:642-646.
9. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia. 2000;20:765-786.
10. Ware JE, Gandek B, for the IQOLA Project Group. The SF-36 health survey: Development and use in mental health research and the IQOLA project. Int J Mental Health. 1994;23:49-73.
11. Limmroth V, Michel MC. The prevention of migraine. Br J Clin Pharmacol. 2001;52:237-243.
12. Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: A meta-analytic review. Headache. 1991;31:333-340.
13. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence-based Guidelines for Migraine Headache in the Primary Care Setting: Pharmacological Management for Prevention of Migraine. Available at: http://www.aoa-net.org/MembersOnly /hcprevent.pdf. Accessed May 12, 2002.
14. Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses. Cephalalgia. 2002;22:209-221.
15. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: A double-blind study versus placebo. Cephalalgia. 1992;12:81-84.
16. Mathew NT. Antiepileptic drugs in migraine prevention. Headache. 2001;41:S18-S24.
17. van der Kuy PH, Lohman JJ. A quantification of the placebo response in migraine prophylaxis. Cephalalgia. 2002;22:265-270.
18. Allen AM, Moeller I, Jenkins TA, et al. Angiotensin receptors in the nervous system. Brain Res Bull. 1998;47:17-28.
19. 1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke. 2000;31:2478-2486.
20. Mendelsohn FA, Jenkins TA, Berkovic SF. Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res. 1993; 613:221-229.
21. Baltatu O, Afeche SC, Jose dos Santos SH, et al. Locally synthesized angiotensin modulates pineal melatonin generation. J Neurochem. 2002;80:328-334.
22. Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-kappa B as a molecular target for migraine therapy. Ann Neurol. 2002;51:507-516.
23. 2 receptors. J Am Soc Nephrol. 2002;13:1162-1171.
24. Kirk JK. Angiotensin-II receptor antagonists: Their place in therapy. Am Fam Physician. 1999;59:3140-3148.
25. Tanaka H, Teramoto S, Oashi K, et al. Effects of candesartan on cough and bronchial hyperresponsives in mildly to moderately hypertensive patients with symptomatic asthma. Circulation. 2001;104:281-285.